Morgan Hakki1, Sunwen Chou. 1. Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA.
Abstract
PURPOSE OF REVIEW: This review assesses recently published data on cytomegalovirus (CMV) antiviral drug resistance. RECENT FINDINGS: Resistance is typically encountered after prolonged ganciclovir treatment for posttransplant primary CMV infection and is diagnosed by the detection of characteristic mutations in the viral UL97 kinase and UL54 DNA polymerase genes in clinical specimens. One of seven canonical UL97 mutations is detected in most cases of ganciclovir resistance, but many viral sequence variants of unknown relevance are being reported after drug exposure in vitro and in vivo. Rapid technical advances in recombinant phenotyping have shown that many of these variants confer no detectable drug resistance, whereas some unusual resistance mutations are newly confirmed. All currently marketed CMV antiviral drugs, including foscarnet and cidofovir, target the viral DNA polymerase, and cross-resistance may result from some UL54 mutations. To decrease cross-resistance and toxicity, there is an ongoing effort to develop anti-CMV drugs with different resistance pathways and alternative targets, such as the UL97 kinase or UL56-UL89 terminase enzymes. SUMMARY: An increasing volume of information correlating CMV genotypes and drug susceptibility phenotypes is becoming available. This will improve the interpretation of sequence-based assays currently used for clinical diagnosis and guide the development of new antiviral drugs.
PURPOSE OF REVIEW: This review assesses recently published data on cytomegalovirus (CMV) antiviral drug resistance. RECENT FINDINGS: Resistance is typically encountered after prolonged ganciclovir treatment for posttransplant primary CMV infection and is diagnosed by the detection of characteristic mutations in the viral UL97 kinase and UL54 DNA polymerase genes in clinical specimens. One of seven canonical UL97 mutations is detected in most cases of ganciclovir resistance, but many viral sequence variants of unknown relevance are being reported after drug exposure in vitro and in vivo. Rapid technical advances in recombinant phenotyping have shown that many of these variants confer no detectable drug resistance, whereas some unusual resistance mutations are newly confirmed. All currently marketed CMV antiviral drugs, including foscarnet and cidofovir, target the viral DNA polymerase, and cross-resistance may result from some UL54 mutations. To decrease cross-resistance and toxicity, there is an ongoing effort to develop anti-CMV drugs with different resistance pathways and alternative targets, such as the UL97 kinase or UL56-UL89 terminase enzymes. SUMMARY: An increasing volume of information correlating CMV genotypes and drug susceptibility phenotypes is becoming available. This will improve the interpretation of sequence-based assays currently used for clinical diagnosis and guide the development of new antiviral drugs.
Authors: D R Kaul; S Stoelben; E Cober; T Ojo; E Sandusky; P Lischka; H Zimmermann; H Rubsamen-Schaeff Journal: Am J Transplant Date: 2011-05 Impact factor: 8.086
Authors: Scott M Palmer; Ajit P Limaye; Missy Banks; Dianne Gallup; Jeffrey Chapman; E Clinton Lawrence; Jordan Dunitz; Aaron Milstone; John Reynolds; Gordon L Yung; Kevin M Chan; Robert Aris; Edward Garrity; Vincent Valentine; Jonathan McCall; Shein-Chung Chow; Robert Duane Davis; Robin Avery Journal: Ann Intern Med Date: 2010-06-15 Impact factor: 25.391
Authors: Justin M Reitsma; John Paul Savaryn; Katherine Faust; Hiromi Sato; Brian D Halligan; Scott S Terhune Journal: Cell Host Microbe Date: 2011-02-17 Impact factor: 21.023
Authors: Brian G Gentry; Jeremy P Kamil; Donald M Coen; Jiri Zemlicka; John C Drach Journal: Antimicrob Agents Chemother Date: 2010-06-14 Impact factor: 5.191
Authors: Malaya K Sahoo; Martina I Lefterova; Fumiko Yamamoto; Jesse J Waggoner; Sunwen Chou; Susan P Holmes; Matthew W Anderson; Benjamin A Pinsky Journal: J Clin Microbiol Date: 2013-08-28 Impact factor: 5.948
Authors: Michael Boeckh; W Garrett Nichols; Roy F Chemaly; Genovefa A Papanicolaou; John R Wingard; Hu Xie; Karen L Syrjala; Mary E D Flowers; Terry Stevens-Ayers; Keith R Jerome; Wendy Leisenring Journal: Ann Intern Med Date: 2015-01-06 Impact factor: 25.391
Authors: Jennifer T Miller; Haiyan Zhao; Takashi Masaoka; Brittany Varnado; Elena M Cornejo Castro; Vickie A Marshall; Kaivon Kouhestani; Anna Y Lynn; Keith E Aron; Anqi Xia; John A Beutler; Danielle R Hirsch; Liang Tang; Denise Whitby; Ryan P Murelli; Stuart F J Le Grice Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191